Press Releases

Vitaeris Announces Multiple Scientific Presentations Involving Clazakizumab at the 2019 American Transplant Congress

VANCOUVER, Canada, May 22, 2019 –Vitaeris Inc. (Vitaeris) today announced that eight abstracts involving or related to clazakizumab, Vitaeris’ proprietary anti-interleukin-6 humanized monoclonal antibody, have been accepted for presentation at the 2019 American Transplant Congress (ATC) taking place from June 1-5 in Boston, MA…

Click here to read more.

Vitaeris and CSL Announce Strategic Partnership with Option to Acquire

MELBOURNE, Australia and VANCOUVER, Canada, December 5, 2017 – CSL Limited (ASX:CSL; USOTC:CSLLY) and Vitaeris Inc. (Vitaeris) today announced that they have entered into a strategic collaboration and purchase option agreement to expedite the development of clazakizumab (an anti-IL6 MAB, formerly ALD518) as a therapeutic option for solid organ transplant rejection…

Click here to read more.

Vitaeris Announces Seed Financing and Appointment of Executive Team

VANCOUVER, British Columbia, June 6, 2016 – Vitaeris Inc., a clinical-stage biopharmaceutical company focused on innovative applications in chronic inflammatory diseases, today announced it has closed a US$7 million seed round financing, including participation by key founding investor HBM Healthcare Investments AG. This financing will enable Vitaeris to initiate operations and advance the best-in-class anti-interleukin-6 (IL-6) monoclonal antibody, clazakizumab, into new clinical studies…

Click here to read more.​

​Alder BioPharmaceuticals Licenses Clazakizumab Rights to Vitaeris

BOTHELL, Wash., and VANCOUVER, British Columbia, May 6, 2016 – Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, and Vitaeris Inc., a newly formed company that will pursue innovative therapeutic indications in chronic inflammatory diseases, today announced that Alder has licensed the exclusive worldwide rights to clazakizumab to Vitaeris In exchange for the rights to clazakizumab, Alder has received an equity stake in Vancouver, British Columbia, based Vitaeris and is eligible to receive royalties and certain other payments. In addition, Randall C. Schatzman, Ph.D., president and chief executive officer of Alder, has joined Vitaeris’ board of directors…

Click here to read more.

Vitaeris is now part of CSL Behring! We are pleased to become part of CSL Behring, a well-established, global industry leader, and know that the future of clazakizumab is in excellent hands. Together, we have already achieved much progress through our partnership over the past few years and are now in an even stronger position to realize our collective goal of addressing one of the greatest unmet needs in the organ transplant community.

Learn more